共 1410 条
[1]
Maemondo M(2010)Gefitinib or chemotherapy for non-small-cell lung Cancer with mutated EGFR N Engl J Med 362 2380-2388
[2]
Inoue A(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[3]
Kobayashi K(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-742
[4]
Sugawara S(2014)Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15 213-222
[5]
Oizumi S(2017)Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 376 629-640
[6]
Isobe H(2018)Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer N Engl J Med 378 113-125
[7]
Gemma A(2007)Identification of the transforming Nature 448 561-566
[8]
Harada M(2014) fusion gene in non-small-cell lung cancer N Engl J Med 371 2167-2177
[9]
Yoshizawa H(2014)First-line crizotinib versus chemotherapy in Cancer Discov 4 662-673
[10]
Kinoshita I(2014)-positive lung cancer Lancet Oncol 15 1119-1128